comparing glp-1 agonists Receptor glp-1 comparison chart Emergence of

Description

Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, et al

These trials have shown reductions in heart failure symptoms and physical limitations and greater improvement in exercise function and have led to growing interest in new ways to address HFpEF, a condition with limited guideline direct medication therapy compared to heart failure with reduced ejection fraction (HFrEF)

Doctors at Continental Hospitals are trained in managing GLP-1 drug therapy and offer complete support from diagnosis to follow-up care

Over the years, several serious risks have been postulated notably pancreatitis[33], pancreatic cancer[34,35], and thyroid cancer[35] but extensive research has not confirmed these fears in humans [36]

Competitive Landscape Some of the Key Players in GLP-1 Market: AstraZeneca plc Boehringer Ingelheim International GmbH Eli Lilly and Company Innogen Pharmaceutical Technology Co., Ltd